Meeting
2014 Genitourinary Cancers Symposium
Peculiar study: Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer.
Authors
Jae-Lyun Lee
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Jae-Lyun Lee , Se-Hoon Lee , Yoon Ji Choi , Jin-Hee Ahn , Cheryn Song , Bum-Sik Hong , Jun Hyuk Hong , Choung-Soo Kim , Hanjong Ahn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Prostate, Penile, Urethral, and Testicular Cancers, and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Urothelial Carcinoma
Clinical Trial Registration Number
NCT01490437
Citation
J Clin Oncol 32, 2014 (suppl 4; abstr 301)
DOI
10.1200/jco.2014.32.4_suppl.301
Abstract #
301
Poster Bd #
G7
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
ATOMIC-Meso: A randomized phase 2/3 trial of ADI-PEG20 or placebo with pemetrexed and cisplatin in patients with argininosuccinate synthetase 1-deficient non-epithelioid mesothelioma.
First Author: Peter Wojciech Szlosarek
Poster
2013 ASCO Annual Meeting
A randomized phase II study adding axitinib to pemetrexed-cisplatin in patients with malignant pleural mesothelioma (MPM): Clinical results of a single-center trial.
First Author: Wieneke A. Buikhuisen
Poster
2012 ASCO Annual Meeting
Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma (MPM).
First Author: Lee M. Krug
Poster
2021 ASCO Annual Meeting
Regorafenib (R) in advanced solitary fibrous tumor (SFT): Results from an exploratory phase II clinical study.
First Author: Silvia Stacchiotti